United States Third Circuit

ResetAA Font size: Print

In Re Lipitor Antitrust Litigation, 14-4202

Reversing the District Court dismissal of complaints in litigation that alleged Lipitor's fraudulent patent procurement and other misconduct because the allegations were plausible, and reversing the dismissal of allegations in Effexor litigation because it was plausible that the companies holding the pharmaceutical patents and generic manufacturers entered into reverse payment settlement agreements that subjected them to antitrust scrutiny.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/08/21




  • United States Third Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  View More Jobs

    View More